Genmab AS Aktie - GE9

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

167,60

Gebot

166,60

Fragen

168,55

Volumen

582

166,40 Tagesbereich 175,15

166,40 52-Wochen-Bereich 281,20

Marktkapitalisierung

11,01B

Handelsende

174,40

Handelsbeginn

175,15

Letzte Trade

166.94999

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

583

Ausgegebene Aktien

65.691.573

Dividendenrendite

Kurs-Gewinn-Verhältnis

1,46

Gewinn pro Aktie (EPS)

119,41

Erlöse

21,53B

Nettogewinn

7,84B

Sektor

Biological Pds,ex Diagnstics

Branche

Biogenetic (human)

Website

www.genmab.com

Hauptsitz

Copenhagen, Dnk

Gegründet

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GE9. The last closing price for Genmab AS was 174,40 €. Over the last year, Genmab AS shares have traded in a share price range of 166,40 € to 281,20 €.

Genmab AS currently has 65.691.573 shares in issue. The market capitalisation of Genmab AS is 11,46 € billion. Genmab AS has a price to earnings ratio (PE ratio) of 1.46.

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company...

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer Media Release...

Transactions in connection with share buy-back program

Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On...

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer...

Genmab Announces Initiation of Share Buy-Back Program

Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total...

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. Company Announcement AbbVie Inc. files complaint...

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer Media...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company...

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to...

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 Company Announcement Johnson & Johnson has decided that it will not...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-19.6	-10.4700854701	187.2	187.2	166.4	285	175.10839185	DE
4	-50.6	-23.1897341888	218.2	223.7	166.4	641	188.23026131	DE
12	-47.2	-21.9739292365	214.8	223.8	166.4	583	196.56164227	DE
26	-46.3	-21.6456287985	213.9	223.8	166.4	450	200.15127574	DE
52	-104.4	-38.3823529412	272	281.2	166.4	322	214.55761714	DE
156	-172.4	-50.7058823529	340	362.9	166.4	255	228.74419373	DE
260	-206	-55.1391862955	373.6	374.3	166.4	216	229.22363442	DE

GE9 - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?

The current share price of Genmab AS is 167,60 €

How many Genmab AS shares are in issue?

Genmab AS has 65.691.573 shares in issue

What is the market cap of Genmab AS?

The market capitalisation of Genmab AS is EUR 11,46B

What is the 1 year trading range for Genmab AS share price?

Genmab AS has traded in the range of 166,40 € to 281,20 € during the past year

What is the PE ratio of Genmab AS?

The price to earnings ratio of Genmab AS is 1,46

What is the cash to sales ratio of Genmab AS?

The cash to sales ratio of Genmab AS is 0,53

What is the reporting currency for Genmab AS?

Genmab AS reports financial results in DKK

What is the latest annual turnover for Genmab AS?

The latest annual turnover of Genmab AS is DKK 21,53B

What is the latest annual profit for Genmab AS?

The latest annual profit of Genmab AS is DKK 7,84B

What is the registered address of Genmab AS?

The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260

What is the Genmab AS website address?

The website address for Genmab AS is www.genmab.com

Which industry sector does Genmab AS operate in?

Genmab AS operates in the BIOGENETIC (HUMAN) sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AMIMedondo Holding AG	0,468 € (72,06%)	100
70BB&S Group SA	5,83 € (49,30%)	92,84k
1AJ2Vision Lithium Inc	0,02 € (37,93%)	157k
C0OVital Battery Metals Inc	0,078 € (34,95%)	96,1k
137Aldeyra Therapeutics Inc	1,724 € (34,32%)	70,84k
6Q5Fathom Nickel Inc	0,01 € (-43,82%)	20k
HXB2AIM ImmunoTech Inc	0,0625 € (-41,04%)	52,5k
4EAQPM Energy Ltd	0,0135 € (-37,21%)	148k
338BCDN Maverick Capital Corp	0,075 € (-33,63%)	26,7k
7BC0Forte Group Holdings Inc	0,202 € (-32,21%)	2,09k
D7GNel ASA	0,197 € (-2,81%)	6,89M
3CPXiaomi Corporation	4,921 € (-7,74%)	5,11M
TKAThyssenkrupp AG	7,99 € (-13,58%)	2,67M
BPE5BP plc	4,35 € (-8,90%)	2,51M
VODIVodafone Group plc	0,7848 € (-6,84%)	2,51M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Genmab AS

GE9 Neueste Nachrichten

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

GE9 - Frequently Asked Questions (FAQ)

Beweger

GE9 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9) Börsenkurse

Genmab AS (GE9)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Genmab AS

GE9 Neueste Nachrichten

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

GE9 - Frequently Asked Questions (FAQ)

Beweger

GE9 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen